EnClear Therapies
EnClear Therapies: A US-based life sciences company developing devices for neurodegenerative disease treatment.
Founded
2018EnClear Therapies: A US-based life sciences company developing devices for neurodegenerative disease treatment.
EnClear Therapies, founded in Cambridge, USA, is a life sciences company dedicated to developing device-based therapies for neurodegenerative diseases. Their core mission is to improve and extend the lives of patients suffering from central nervous system (CNS) diseases through precision dosing. The company’s flagship product, the EnTrega CSF Platform, focuses on removing toxic proteins from cerebrospinal fluid (CSF) and has applications in neuro-oncology and other CNS disorders. EnClear Therapies aims to leverage partnerships to expand its reach into various neurodegenerative and lysosomal storage diseases.
Notable affiliated individuals and investors include experts in neurology and biotechnology, though specific names are not publicly highlighted. Key achievements of EnClear Therapies include the development of their proprietary EnTrega CSF Platform, which represents a significant advancement in the treatment of CNS diseases. The overall impact of EnClear Therapies lies in their innovative approach to treating debilitating neurological conditions, potentially offering new hope and improved quality of life for patients worldwide.
Companies similar to EnClear Therapies include CuraSen Therapeutics, Csfrefresh, Lysosomal Therapeutics and Aztherapies.
EnClear Therapies was founded in 2018.
EnClear Therapies' headquarters is located in Cambridge, MA, US.
EnClear Therapies' most recent funding round was for $10M (USD) in February 2020.
As of Feb 19, 2020, EnClear Therapies has disclosed funding of $12M (USD). Undisclosed round amounts are excluded.
EnClear Therapies has 12 employees as of Feb 4, 2024.
Aztherapies
